

# A comprehensive evaluation of the genetic architecture of sudden cardiac arrest

Foram N. Ashar<sup>1†</sup>, Rebecca N. Mitchell<sup>1†</sup>, Christine M. Albert<sup>2</sup>, Christopher Newton-Cheh<sup>3</sup>, Jennifer A. Brody<sup>4</sup>, Martina Müller-Nurasyid<sup>5,6,7,8</sup>, Anna Moes<sup>1</sup>, Thomas Meitinger<sup>8,9,10</sup>, Angel Mak<sup>11</sup>, Heikki Huikuri<sup>12</sup>, M. Juhani Juntila<sup>12</sup>, Philippe Goyette<sup>13</sup>, Sara L. Pulit<sup>14</sup>, Raha Pazoki<sup>15</sup>, Michael W. Tanck<sup>16</sup>, Marieke T. Blom<sup>17</sup>, XiaoQing Zhao<sup>18</sup>, Aki S. Havulinna<sup>19</sup>, Reza Jabbari<sup>20</sup>, Charlotte Glinge<sup>20</sup>, Vinicius Tragante<sup>21</sup>, Stefan A. Escher<sup>22</sup>, Aravinda Chakravarti<sup>1</sup>, Georg Ehret<sup>1</sup>, Josef Coresh<sup>23</sup>, Man Li<sup>23</sup>, Ronald J. Prineas<sup>24</sup>, Oscar H. Franco<sup>25,26</sup>, Pui-Yan Kwok<sup>11</sup>, Thomas Lumley<sup>27</sup>, Florence Dumas<sup>28</sup>, Barbara McKnight<sup>4,29</sup>, Jerome I. Rotter<sup>30</sup>, Rozenn N. Lemaitre<sup>4</sup>, Susan R. Heckbert<sup>31</sup>, Christopher J. O'Donnell<sup>32,33</sup>, Shih-Jen Hwang<sup>33</sup>, Jean-Claude Tardif<sup>13</sup>, Martin VanDenburgh<sup>2</sup>, André G. Uitterlinden<sup>34</sup>, Albert Hofman<sup>26</sup>, Bruno H. C. Stricker<sup>26</sup>, Paul I. W. de Bakker<sup>35,36</sup>, Paul W. Franks<sup>22</sup>, Jan-Hakan Jansson<sup>37</sup>, Folkert W. Asselbergs<sup>21,38,39</sup>, Marc K. Halushka<sup>40</sup>, Joseph J. Maleszewski<sup>41</sup>, Jacob Tfelt-Hansen<sup>20,42</sup>, Thomas Engström<sup>20,43</sup>, Veikko Salomaa<sup>19</sup>, Renu Virmani<sup>18</sup>, Frank Kolodgie<sup>18</sup>, Arthur A. M. Wilde<sup>44</sup>, Hanno L. Tan<sup>44</sup>, Connie R. Bezzina<sup>44</sup>, Mark Eijgelsheim<sup>45</sup>, John D. Rioux<sup>13</sup>, Xavier Jouven<sup>28</sup>, Stefan Kääh<sup>7,8</sup>, Bruce M. Psaty<sup>46</sup>, David S. Siscovick<sup>47</sup>, Dan E. Arking<sup>1\*†</sup>, Nona Sotoodehnia<sup>48\*†</sup>; for the SCD working group of the CHARGE Consortium

<sup>1</sup>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins, 733 N Broadway, Baltimore, MD 21205, USA; <sup>2</sup>Divisions of Preventive Medicine and Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave East, 3rd Floor, Boston, MA 02215, USA; <sup>3</sup>Center for Human Genetic Research & Cardiovascular Research Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; <sup>4</sup>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 1730 Minor Ave, Seattle, WA 98101, USA; <sup>5</sup>Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany; <sup>6</sup>Chair of Genetic Epidemiology, Institute for Medical Informatics, Biometry and Epidemiology, Faculty of Medicine, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany; <sup>7</sup>Department of Internal Medicine I (Cardiology), Hospital of the Ludwig-Maximilians-University, Marchioninistr. 15, 81377 Munich, Germany; <sup>8</sup>DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Biedersteiner Strasse 29, 80802 Munich, Germany; <sup>9</sup>Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany; <sup>10</sup>Institute of Human Genetics, der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; <sup>11</sup>Cardiovascular Research Institute and Institute for Human Genetics, University of California, San Francisco, 1550 4th Street, San Francisco, CA 94158, USA; <sup>12</sup>Research Unit of Internal Medicine, University Hospital and University of Oulu, Kajaaninkatu 50, 90014 Oulu, Finland; <sup>13</sup>Montreal Heart Institute, Université de Montréal, 5000 rue Bélanger, Montréal, Quebec H1T 1C8, Canada; <sup>14</sup>Department of Genetics, Center for Molecular Medicine, University Medical Centre Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands; <sup>15</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St Mary's Hospital, Praed St, Paddington, London W2 1NY, UK; <sup>16</sup>Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; <sup>17</sup>Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; <sup>18</sup>CVPath Institute, 19 Firstfield Road, Gaithersburg, MD 20878, USA; <sup>19</sup>National Institute for Health and Welfare, Mannerheimintie 166, FI-00271 Helsinki, Finland; <sup>20</sup>Department of Cardiology, Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark; <sup>21</sup>Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands; <sup>22</sup>Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Barngatan 4, Skånes universitetssjukhus, 222 42 Malmö, Sweden; <sup>23</sup>Department of Epidemiology, Johns Hopkins University, 615 N Wolfe Street, Baltimore, MD 21205, USA; <sup>24</sup>Public Health Sciences, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA; <sup>25</sup>Institute of Social and Preventative Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; <sup>26</sup>Department of Epidemiology, Erasmus MC, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands; <sup>27</sup>Department of Statistics, University of Auckland, Private Bag 92014, Auckland 1142, New Zealand; <sup>28</sup>Paris Sudden Death Expertise Center, University Paris Descartes, Sorbonne Paris Cité, INSERM U970, 56 rue Leblanc, Paris 75015 France; <sup>29</sup>Department of Biostatistics, University of Washington, F-600, Health Sciences Building 1705 NE Pacific Street, Seattle, WA 98195, USA; <sup>30</sup>The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA;

\* Corresponding author. Tel: 410-502-4867, Fax: 410-614-8600, Email: arking@jhmi.edu (D.E.A.); Tel: 206-520-5000, Fax: 206-221-2662, Email: nsotoo@u.washington.edu (N.S.)

† The first and last two authors contributed equally to the study.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

<sup>31</sup>Cardiovascular Health Research Unit, Department of Epidemiology, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA; <sup>32</sup>NHLBI Framingham Heart Study, 73 Mount Wayte Avenue, Suite #2, Framingham, MA 01702, USA; <sup>33</sup>Cardiology Section, Department of Medicine, Boston VA Healthcare System, 1400 VFW Parkway, Boston, MA 02132, USA; <sup>34</sup>Erasmus MC University Medical Center, Department of Internal Medicine, Dr. Molewaterplein 40, 3015 CD Rotterdam, The Netherlands; <sup>35</sup>Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands; <sup>36</sup>Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands; <sup>37</sup>Department of Public Health and Clinical Medicine, Research Unit Skelleftea, Umea University, University Hospital, Building 1A, 4st, 901 85 Umea, Sweden; <sup>38</sup>Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK; <sup>39</sup>Institute of Health Informatics, University College London, 222 Euston Road London, NW1 2DA, UK; <sup>40</sup>Department of Pathology, Division of Cardiovascular Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross Rm 632B, Baltimore, MD 21205, USA; <sup>41</sup>Department of Laboratory Medicine & Pathology, Mayo Clinic, 3050 Superior Drive, Rochester, MN 55901, USA; <sup>42</sup>Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark; <sup>43</sup>Department of Cardiology, University of Lund, Getingevägen 4, 222 42 Lund, Sweden; <sup>44</sup>Amsterdam UMC, University of Amsterdam, Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands; <sup>45</sup>Department of Nephrology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands; <sup>46</sup>Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, 1730 Minor Ave, suite #1360, Seattle, WA 98101, USA; <sup>47</sup>The New York Academy of Medicine, 1216 5th Ave, New York, New York 10026, USA; and <sup>48</sup>Cardiovascular Health Research Unit, Division of Cardiology, Departments of Medicine and Epidemiology, University of Washington, 1730 Minor Ave, Seattle, WA 98101, USA

Received 19 January 2018; revised 17 April 2018; editorial decision 20 July 2018; accepted 20 July 2018; online publish-ahead-of-print 28 August 2018

See page 3970 for the editorial comment on this article (doi: 10.1093/eurheartj/ehy508)

## Aims

Sudden cardiac arrest (SCA) accounts for 10% of adult mortality in Western populations. We aim to identify potential loci associated with SCA and to identify risk factors causally associated with SCA.

## Methods and results

We carried out a large genome-wide association study (GWAS) for SCA ( $n = 3939$  cases, 25 989 non-cases) to examine common variation genome-wide and in candidate arrhythmia genes. We also exploited Mendelian randomization (MR) methods using cross-trait multi-variant genetic risk score associations (GRSA) to assess causal relationships of 18 risk factors with SCA. No variants were associated with SCA at genome-wide significance, nor were common variants in candidate arrhythmia genes associated with SCA at nominal significance. Using cross-trait GRSA, we established genetic correlation between SCA and (i) coronary artery disease (CAD) and traditional CAD risk factors (blood pressure, lipids, and diabetes), (ii) height and BMI, and (iii) electrical instability traits (QT and atrial fibrillation), suggesting aetiologic roles for these traits in SCA risk.

## Conclusions

Our findings show that a comprehensive approach to the genetic architecture of SCA can shed light on the determinants of a complex life-threatening condition with multiple influencing factors in the general population. The results of this genetic analysis, both positive and negative findings, have implications for evaluating the genetic architecture of patients with a family history of SCA, and for efforts to prevent SCA in high-risk populations and the general community.

## Keywords

Sudden cardiac arrest • Genome-wide association study • Mendelian randomization

## Introduction

Sudden cardiac arrest (SCA) is a major cause of cardiac mortality, affecting over 300 000 people in the US every year.<sup>1</sup> Clinical and autopsy studies have demonstrated a predominant, common pathophysiology in Western populations: the most common electrophysiologic mechanism for SCA is ventricular fibrillation (VF) and the most common pathologic substrate is coronary artery disease (CAD). Despite recent increases in SCA survival rates,<sup>2</sup> survival remains low, and an important way to impact SCA mortality is through risk stratification and prevention. Although observational studies have identified numerous clinical and subclinical risk factors for SCA, understanding which of these associations are causal will help target prevention strategies.

Family history of SCA is a strong risk factor for SCA in the general population, suggesting that genetic variation may influence SCA risk.<sup>3–5</sup> While patients with inherited arrhythmias (e.g. long QT syndrome) are at increased SCA risk,<sup>6–8</sup> the vast majority of SCA occurs outside of this high-risk population. Whether common variation in ion channel genes or other genomic regions

influences SCA risk and identifies those at higher risk remains largely unknown.

Examining the genomic architecture of SCA allows us not only to examine genomic risk markers for SCA but also to assess causal relationships of clinical and subclinical risk factors with SCA. Mendelian randomization (MR) methods exploit the fact that genetic variants are largely determined at conception and randomly distributed in populations, to determine whether an exposure may be causally associated with the outcome, and to estimate the effect size of that causal association.<sup>9–11</sup> Here, we use a multi-single nucleotide polymorphism (SNP) Genetic Risk Score Association (GRSA) model to compare genetic associations of known SCA risk factors to genetic associations with SCA as an effective way to understand the potential underlying causal pathways and processes that modulate SCA risk.

To determine whether genetic variants are associated with SCA risk, we performed a genome-wide association study (GWAS) for SCA. We additionally examined whether common variation in inherited arrhythmia genes was associated with SCA risk in the general population. We then evaluated the relationships between SCA and multi-SNP GRSA for each risk factor.

## Methods

### Study populations and phenotype definition

The overall study design is summarized in [Supplementary material online, Figure S1](#). Briefly, nine studies of European-descent individuals (3939 cases and 25 989 non-cases) comprised a GWAS 'discovery' stage, and 12 studies with individuals of European, African, and Asian descent (4918 additional cases and 21 873 controls) comprised a 'replication' stage. Study descriptions, along with study-specific SCA definitions and genotyping methods, are detailed in the [Supplementary material online, Appendix](#). All studies were approved by appropriate local institutional review boards.

### Genome-wide association study

Genome-wide genotype data was imputed to the HapMap2-CEU reference panel, following study-level quality control checks ([Supplementary material online, Table S1A](#)). Each 'discovery' study performed regression analysis adjusted for age, sex, and study-specific covariates, and results were meta-analysed using inverse-variance meta-analysis implemented in METAL.<sup>12</sup> Meta-analysis was performed with results from 9 GWASs comprising a total of 3939 European-ancestry cases and 25 989 controls ([Supplementary material online, Table S1A](#)), with additional genotyping of 26 SNPs in up to 4918 cases and 21 879 controls of European, African, and Asian descent ([Supplementary material online, Table S1B](#)). For SNP rs1554218, ARIC samples were not included in the discovery data leaving 3815 cases and 17 107 controls for the discovery stage. These ARIC samples were used only in the replication data resulting in 5218 cases and 35 957 controls for the replication stage for analysis involving this SNP only. The replication set included an additional ~120 ARIC cases not present in the discovery set. Therefore, the decision was made to remove the ARIC samples from the discovery dataset to use them in the replication dataset for this SNP. The top 26 SNPs were examined in a 'replication' population ([Supplementary material online, Table S1B](#)). Findings from 'discovery' and 'replication' stages were then meta-analysed ([Supplementary material online, Table S2, Figure S3A](#)). Additionally, exploratory GWASs restricted to men, women, individuals under age 65, and cases with VF/shockable rhythm were performed ([Supplementary material online, Table S3, Figure S3B–E](#)).

### Candidate genes

Using results from the GWAS meta-analysis, we examined variants in 54 inherited arrhythmia genes using the 'logistic-minsnp-gene-perm' function in FASTv1.8.<sup>13</sup> This best single-SNP permutation based *P*-value is corrected for gene size by performing up to 1 million permutations per gene. Gene boundaries were defined by RefSeq gene coordinates on build GRCh37 with ±10 kb flanking sequence.

### Mendelian randomization instrument

Observational studies examine association of an exposure [e.g. body mass index (BMI)] with an outcome (e.g. SCA) but cannot assess causality. Unobserved variables affecting both exposure and outcome may confound these associations and lead to biased estimates of association. Mendelian randomization is based on the assumption that because genetic variants are determined at conception and are randomly distributed in large populations, they are unassociated with potential confounders. Therefore, under certain assumptions such as the absence of genetic pleiotropy, genetic variants used as instrumental variables can determine whether an exposure is potentially causally associated with the outcome, and estimate the size of that association (see [Supplementary material online, Appendix](#)). Here, we use a multi-SNP GRSA model to compare genetic associations with SCA with those of known SCA risk factors as an


effective way to understand the underlying causal pathways and processes that influence SCA risk.

### Genetic Risk Score Association

We estimated a separate GRSA for each of the following: (1) CAD and traditional CAD risk factors, including type 2 diabetes (T2D), fasting glucose adjusted for BMI (FGadjBMI), fasting insulin adjusted for BMI (FladjBMI), diastolic blood pressure (DBP), systolic blood pressure (SBP), total cholesterol (TCH), and triglycerides (TG); (2) cardiac electrophysiologic factors, including atrial fibrillation (AF), heart rate (HR), QRS interval (QRS), and QT interval (QT); and (3) anthropometric traits, including BMI, waist circumference adjusted for BMI (WCadjBMI), waist to hip ratio adjusted for BMI (WHRadjBMI), and height. [Supplementary material online, Table S4](#) details the 18 traits, and the source published GWAS used to construct the GRSA models for these traits.

To estimate GRSA for each putative SCA risk factor, we examined genome-wide SNPs associated with the risk trait following stringent linkage disequilibrium (LD)-pruning ([Supplementary material online, Appendix](#)). The associations of these SNPs with the risk factors and the SCA outcome are used to calculate an inverse-variance weighted multi-SNP GRSA as implemented in the R-package 'gtx'.<sup>14</sup> This GRSA can be interpreted as an inverse-variance weighted, meta-analysed (over SNPs) estimate of the causal log odds ratio (OR) for SCA associated with a 1 SD higher value of the risk factor from a MR analysis.<sup>15</sup> It is computationally equivalent to the slope estimate from a zero-intercept linear regression with log OR for the association of an additional variant allele in SNPs with SCA ( $\beta_{SCA}$ ) as the dependent variable and the mean difference associated with one additional variant allele in SNPs on the risk factor trait ( $\beta_{trait}$ ) as the independent variable, weighted by the standard error of the  $\beta_{SCA}$  squared ( $SE_{SCA}^2$ ) ([Figure 1A](#)) (more details in [Supplementary material online, Appendix](#)). We evaluated the use of other MR methods, including MR-Egger, simple median, and median-weighted. However, we found while these produced similar GRSA estimates as the inverse-weighted (IVW) method, these other methods had lower power ([Supplementary material online, Figure S4 and Table S5](#)). We therefore only report the results from the IVW method. We also used the intercept test from the MR-Egger method to evaluate the presence of pleiotropy in our analyses ([Supplementary material online, Table S5](#)).

The validity of this analysis requires that SNPs included can only affect the outcome through their effects on the risk factor (i.e. no horizontal pleiotropy). If there is no pleiotropy, the SNPs contributing the GRSA estimate should all estimate the same magnitude causal association between risk factor and SCA. We use the heterogeneity independent instrument (HEIDI)-outlier method from the 'gsmr' R package to detect and remove potentially pleiotropic SNPs.<sup>16</sup> Note that we report GRSA estimates from analyses only including SNPs that meet a stringent genome-wide significant (GWS) *P*-value cut-off ( $P < 5 \times 10^{-8}$ ), GRSA<sub>GWS</sub>, as SNPs at this significance level likely are true positives and reliable instruments. However, the power for MR is dependent on the variance explained by the SNPs included in the GRSA, and for complex traits, the majority of the true signals may lie in SNPs that do not meet genome-wide significance. Therefore, we identified a somewhat arbitrary *P*-value cut-off based on visual inspection of the variance explained plots that largely maximizes variance explained while minimizing the number of SNPs ([Supplementary material online, Figure S5](#)). We found that all the traits fell between a 0.2 and 0.4 *P*-value cut-off, but the results within a trait were robust to cut-offs chosen between 0.2 and 0.4. We use a GRSA constructed with this custom *P*-value cut-off (GRSA<sub>max</sub>) to assess only the significance of the GRSA ( $P_{max}$ ), as this model has the greatest power to



**Figure 1** Genetic Risk Score Association (GRSA) estimation. The plot (A) illustrates the process by which the QT-SCA Genetic Risk Score Association is calculated using SNPs associated with QT at  $P < 5 \times 10^{-8}$ . The points represent the effect of each SNP on QT (in units of standard deviation of QT) on the x-axis and the log odds effect on sudden cardiac arrest risk (corresponding 95% confidence intervals in grey) on the y-axis. The estimate of the genetic risk score association is the slope of the zero-intercept weighted regression line (solid red line). For the Genetic Risk Score Association used in our analyses, the model contains a genome-wide LD-pruned SNP set (details in Methods section). The top directed acyclic graph (B) represents a scenario in which the trait of interest has a causal effect on the outcome. If the Genetic Risk Score Association, comprised of trait-associated variants (e.g. QT), has a significant effect on the outcome (e.g. sudden cardiac arrest), it supports a causal role for the trait on the outcome. The bottom directed acyl graph (C) presents the case where an association is observed between the trait and outcome, but the Genetic Risk Score Association comprised of trait-associated variants is not significantly associated with the outcome, suggesting that the observational association is likely being mediated by a confounding variable and the trait does not have a causal impact on the outcome.

assess the significance of an association.  $P_{\max}$  is determined by permutation due to inflated test statistics (Supplementary material online, Figure S6 and Supplementary material online, Appendix). At less stringent  $P$ -values, false-positive SNPs may be included resulting in a bias of the estimate toward the confounded association level. Therefore, we do not use the  $\text{GRSA}_{\max}$  to determine the magnitude of the GRSA association, only its direction and significance. We performed two analyses, one using  $\text{GRSA}_{\text{GWS}}$  to evaluate significance and effect size, and secondarily using the  $\text{GRSA}_{\max}$  to evaluate potential associations and directions of effect at maximal power ( $P_{\max}$ ). We performed multiple-testing adjustment on all resulting  $P$ -values ( $P_{\text{GWS}}$  and  $P_{\max}$ ) using a false discovery rate (FDR) cut-off of  $\text{FDR} < 0.05$ .

We similarly computed risk factor GRSA on the outcome of CAD. We use a 1-degree of freedom Wald test to test for difference in  $\text{GRSA}_{\text{GWS}}$  magnitudes between SCA and CAD.

### Sex-specific analyses


We performed sex-specific SCA GWAS analyses to construct trait GRSA separately by sex. Genetic risk score associations were

constructed from the same set of LD-pruned SNPs used for overall  $\text{GRSA}_{\text{GWS}}$  analyses.  $P$ -values for difference in  $\text{GRSA}_{\text{GWS}}$  between sexes were obtained from a 1-degree of freedom Wald test.

## Results

### Genome-wide association study

Meta-analysis was performed with results from 9 GWASs of 3939 European-ancestry cases and 25 989 controls (Supplementary material online, Table S1A, Figure S3A) with additional genotyping of 26 SNPs in up to 4918 cases and 21 879 controls of European, African, and Asian descent (Supplementary material online, Table S1B). No SNPs were associated with SCA ( $P < 5 \times 10^{-8}$ ) (Supplementary material online, Table S2) in the main analysis or in subgroup analyses limited to European-descent individuals, men, women, younger participants ( $\leq 65$  years), or cases with documented VF/shockable rhythm (Supplementary material online, Tables S2 and S3, Figure S3B–E).



**Figure 2** Genetic Risk Scores Association (GRSA) estimates for sudden cardiac arrest. These data points represent the exponentiated Genetic Risk Score Association estimates of 18 traits on sudden cardiac arrest (SCA) and corresponding 95% confidence interval values. The Genetic Risk Score Association estimates in the top panel for the binary traits are in log odds units. Values in bottom panel are in SD units of the quantitative traits. Genetic Risk Score Association estimates and significance are derived from SNPs associated with each trait at  $P < 5 \times 10^{-8}$ . The significance of the  $GRSA_{GWS}$  estimates (false discovery rate adjusted  $P_{GWS}$ ) are represented as '\*' for  $P < 0.05$ , '\*\*' for  $P < 0.01$ , and '\*\*\*' for  $P < 0.001$ . The significance of the secondary analysis using  $GRSA_{max}$  estimates (false discovery rate adjusted permuted  $P_{max}$ ) are represented as '+' for  $P < 0.05$ , '++' for  $P < 0.01$  and '+++' for  $P < 0.001$ . For details on values of Genetic Risk Score Association estimates and  $P$ -values, see [Supplementary material online, Tables S8 and S9](#). AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; DBP, diastolic blood pressure; FGadjBMI, fasting glucose adjusted for BMI; FIadjBMI, fasting insulin adjusted for BMI; HDL, high-density lipoproteins; HR, heart rate; LDL, low-density lipoproteins; QRS, QRS interval; QT, QT interval; SBP, systolic blood pressure; TCH, total cholesterol; TG, triglycerides; T2D, type 2 diabetes; WCadjBMI, waist circumference adjusted for BMI; WHRadBMI, waist-to-hip ratio adjusted for BMI.

## Candidate gene and candidate SNP analyses

Despite sufficient power to detect relative risks of 1.15 (80% power, allele frequency 0.30, at  $\alpha = 0.05$ , after Bonferroni correction for multiple-testing; more details in the [Supplementary material online, Appendix](#)) in a candidate gene analysis, we did not find common variants in inherited arrhythmia genes associated with SCA in the general population ([Supplementary material online, Table S6](#)). Examining SNPs previously associated with SCA in smaller studies, no SNP was found to be associated with SCA at the genome-wide significance threshold. ([Supplementary material online, Table S7](#)).

## Genetic Risk Scores Associations

To explore whether clinical and subclinical risk factors are causally linked with SCA, we examined genetic risk score associations

(GRSA) between SCA and: (1) CAD and traditional CAD risk factors; (2) cardiac electrophysiologic factors; and (3) anthropometric traits. While the results reported below were computed using the IVW method, we used the intercept test of the MR-Egger method to evaluate the possible presence of pleiotropy. While high-density lipoprotein (HDL) was nominally significant ( $P = 0.02$ ), all other traits were not found to be significantly influenced by pleiotropy.

### CAD and CAD risk factors

Prevalent CAD is an important SCA risk factor with ~80% of male SCA survivors having underlying CAD.<sup>17</sup> From  $GRSA_{GWS}$  analysis we show that the difference in CAD status is causally associated with SCA (OR in SCA risk per log odds difference in CAD, 1.36; 95% CI 1.19–1.55;  $P_{GWS} = 9.29 \times 10^{-5}$ ) ([Figure 2, Supplementary material online, Table S8](#)). While traditional CAD risk factors (blood pressure,

lipids, and diabetes) were not significantly associated with SCA at the more restrictive  $GRSA_{GWS}$  threshold, using  $GRSA_{max}$  to maximize power, several additional associations were detected, including type 2 diabetes ( $P_{max} < 0.001$ ), low-density lipoprotein ( $P_{max} = 0.005$ ), total cholesterol ( $P_{max} < 0.001$ ), triglycerides ( $P_{max} < 0.001$ ), DBP ( $P_{max} = 0.0170$ ), and SBP ( $P_{max} = 0.0230$ ) (Supplementary material online, Table S9). In the  $GRSA_{max}$  analysis, variants associated with higher diabetes risk, higher cholesterol and triglyceride levels, and higher SBP and DBP were all associated with higher SCA risk.

### Cardiac electrophysiologic factors

To explore the influence of cardiac electrophysiology on SCA, we examined genetics of electrophysiologic traits associated with SCA: (1) atrial fibrillation, (2) QT interval (ventricular repolarization), (3) QRS interval (ventricular conduction), and (4) heart rate. In the  $GRSA_{GWS}$  analysis, we show that longer QT interval, a risk factor for SCA in the general population, is significantly associated with SCA (OR in SCA risk per SD increase in QT, 1.44; 95% CI 1.13–1.83;  $P_{GWS} = 0.018$ ) (Figure 2, Supplementary material online, Table S8).<sup>18</sup> Using  $GRSA_{max}$ , in addition to QT, we also identified a significant association of AF with SCA ( $P_{max} < 0.001$  for both QT and AF) (Supplementary material online, Table S9). Variants associated with longer QT interval and higher AF risk were associated with higher SCA risk. In contrast, no significant association was seen with QRS or heart rate, even at the more permissive and statistically powerful  $GRSA_{max}$ .

### Anthropometric measures

The BMI  $GRSA_{GWS}$  was significantly associated with SCA (OR for SCA risk per SD higher BMI 1.63; 95% CI 1.23–2.15;  $P_{GWS} = 0.005$ ) (Figure 2, Supplementary material online, Table S8). Using  $GRSA_{max}$ , we found a significant negative association between height and SCA ( $P_{max} < 0.001$ ) (Supplementary material online, Table S9). Variants associated with greater height are associated with lower CAD risk,<sup>19</sup> and we correspondingly observed a negative  $GRSA$  between SCA and height. No significant association was seen with  $GRSAs$  composed of variants associated with measures of central/abdominal adiposity, such as waist-to-hip ratio or waist circumference.

## Contrasting sudden cardiac arrest and coronary artery disease Genetic Risk Score Associations

Given the strong association of CAD with SCA, we compared the magnitudes of risk factor  $GRSA_{GWS}$  on the outcomes of SCA (Figure 2) and CAD (Supplementary material online, Figure S7) to identify traits where risk factors may be more strongly causally associated with SCA than CAD. While the  $GRSA_{GWS}$  for traditional CAD risk factors (blood pressure and lipid traits) are larger for CAD risk than SCA risk, we find that  $GRSA_{GWS}$  for electrophysiologic traits of QT interval (0.34 for SCA vs. 0.096 for CAD,  $P$  for difference = 0.06) and AF (0.097 for SCA vs. -0.029 for CAD,  $P$  for difference = 0.017), there was a suggestion of a larger association with SCA than CAD risk (Figure 3, Supplementary material online, Table S8).

## Sex differences


Sex differences in SCA incidence, underlying SCA pathophysiology, and prevalence of certain risk factors have been well documented,<sup>20</sup> yet little is known about whether the effect of risk factors on SCA differs by sex. Among  $GRSAs_{GWS}$  where a main effect association was identified, we found a nominally significant difference in association between women and men for diabetes (0.240 for women vs. 0.021 for men,  $P$  for difference = 0.05) and HDL (-0.417 for women vs. 0.026 for men,  $P$  for difference = 0.04) (Supplementary material online, Table S10).

## Discussion

Our SCA GWAS demonstrates that while SCA is a complex disease with multiple risk factors, a comprehensive genetic approach can shed light on causal vs. correlational associations. Using MR, we establish that differences in CAD, BMI, and QT interval are causally associated with SCA. Secondary analyses further implicate type 2 diabetes, additional traditional CAD risk factors such as lipids and blood pressure, as well as height and AF.

Despite adequate power to identify relatively modest associations (OR > 1.3), our study did not find evidence that common variation in Mendelian arrhythmia genes is associated with SCA risk in the general population. Since underlying electrical instability is an important cause of SCA, prior smaller studies have examined inherited arrhythmia genes or variants associated with electrophysiologic traits to identify genetic variants that influence SCA risk.<sup>21–23</sup> While rare private mutations in ion channel and other electrophysiology-related genes increase arrhythmia risk in high-risk families and may also increase SCA risk in the general population,<sup>24</sup> our study suggests that common variants in these genes are not significant contributors to SCA in the general population. This may be due to differing underlying genetics between inherited arrhythmias vs. SCA in the general population. In contrast, we do find that  $GRSA$  estimates of phenotypes associated with electrical instability (AF and QT) are causally associated with SCA risk, more so than they are causally associated with CAD. This confirms our understanding of the pathophysiology of SCA; SCA is not simply fatal CAD, but rather, electrical instability also plays a prominent role in influencing SCA risk.

Intriguingly, not all electrophysiologic phenotypes observationally linked to SCA are causally associated with SCA in our analyses. QRS interval and heart rate, two traits observationally associated with SCA,<sup>25,26</sup> failed to show significant evidence of a shared genetic basis with SCA. This lack of association may be due to inadequate power to identify more modest correlations. Alternatively, it may be that the associations from observational studies are confounded by other factors, and not causative (Figure 1B,C). For instance, underlying CAD can lead to both longer QRS interval and increased SCA risk; thus, while observational studies show an association between SCA and both traits (CAD and QRS interval), the association between SCA and QRS interval may not be causal. Similarly, the observational association of higher heart rate with SCA risk may be confounded by higher adrenergic state due to underlying heart disease and not itself be causal. Thus, the  $GRSA$  approach to examining observational risk factors assists in differentiating causative factors from confounded associations.



**Figure 3** Comparison of Genetic Risk Score Association for sudden cardiac arrest and coronary artery disease. These data represent exponentiated Genetic Risk Score Associations of all 17 traits. Genetic Risk Score Association estimates for sudden cardiac arrest and coronary artery disease, are plotted in orange and teal, respectively. Bars around the estimates represent the 95% confidence interval. The Genetic Risk Score Association estimates in the top panel for the binary traits are in log odds units. Values in bottom panel are in SD units of the quantitative traits. The level of significance for 1 degree of freedom Wald test of difference in  $GRSA_{GWS}$  estimates between sudden cardiac arrest and coronary artery disease is represented '\*' for  $P < 0.05$ , '\*\*' for  $P < 0.01$ , and '\*\*\*' for  $P < 0.001$ . AF, atrial fibrillation; BMI, body mass index; DBP, diastolic blood pressure; FGadjBMI, fasting glucose adjusted for BMI; FladjBMI, fasting insulin adjusted for BMI; HDL, high-density lipoproteins; HR, heart rate; LDL, low-density lipoproteins; QRS, QRS interval; QT, QT interval; SBP, systolic blood pressure; TCH, total cholesterol; TG, triglycerides; T2D, type 2 diabetes; WCadjBMI, waist circumference adjusted for BMI; WHRadBMI, waist-to-hip ratio adjusted for BMI.

Coronary artery disease is the most common underlying pathologic substrate for SCA. It is reassuring, therefore, that we find significant estimated causal associations with SCA risk using GRSA models constructed from CAD and traditional CAD risk factors, including blood pressure, diabetes, and cholesterol traits.

Anthropometric measures appear to be causally associated with SCA. Shorter stature is associated with increased SCA risk in observational studies; our findings support the conclusion that this observational association is causal. Observational data on BMI and SCA risk have been conflicting, perhaps due to confounding from smoking status and frailty. Previously,<sup>27</sup> we have shown that increased BMI is associated with increased SCA risk in non-smokers, but not smokers. In this study, we find that differences in BMI, but not central/abdominal obesity, were causally associated with SCA risk. This finding is especially interesting in the context of recent data that imply there is a different biological process underlying BMI and central obesity.<sup>28,29</sup>

Finally, of the traits associated with SCA, we found that GRSA for diabetes and HDL were nominally significantly different between

men and women. While diabetes is a SCA risk factor among both sexes, previous observational studies have consistently suggested a stronger, albeit not statistically different, association among women than men.<sup>30,31</sup> These findings may reflect different underlying SCA pathophysiology between men and women. While these differences may be due to chance as they do not remain significant after multiple test correction, it is also likely that our study is underpowered to detect these differences.

Several limitations deserve consideration. First, without detailed autopsy information, rhythm monitoring, and information on circumstances surrounding the cardiac arrest, the underlying aetiology and mechanism of death may be heterogeneous and genetic associations are likely to be diluted. Nonetheless, clinical and autopsy studies have demonstrated a predominant, common pathophysiology of SCA in Western populations: VF in the setting of CAD. Hence, it is reassuring that our genetic studies suggest an important role for both CAD and electrical instability in SCA. Second, despite ours being the largest exploration of SCA genomics to date, the discovery sample size of

only ~4000 cases, in addition to the heterogeneity of the phenotype, limited our ability to find genetic associations with low frequency variants or variants of modest effect. Hence, while our data do not support screening individuals with a family history of SCA for common variation in inherited arrhythmia genes, much larger samples sizes are needed to address whether rare variation of modest effect in these genes influence SCA risk. Third, the validity of the GRSAs as a MR instrument rests on the assumption that the variant causes differences in the outcome only by its effects on the risk factor of interest, and not directly or by influencing other risk factors. Although we did not explicitly exclude SNPs associated with multiple risk factors (genetic pleiotropy), we did utilize a goodness-of-fit approach to exclude putative 'pleiotropic' effects from all GRSAs. Furthermore, we performed a sensitivity analysis using the MR-Egger method, which tests for the presence of pleiotropy. Only HDL was found to be significantly influenced by pleiotropy ( $P = 0.02$ ). Lastly, while genetic pleiotropy can bias our conclusions, important influence is less likely when using multiple SNPs aggregated in a genetic risk score.<sup>32</sup> Finally, the lack of common variants exhibiting large effect sizes associated with SCA limits the potential clinical utility for risk prediction.

In conclusion, while we were not able to identify any common genetic variants significantly associated with SCA risk through the GWAS, as well as any common variation in specific inherited arrhythmia genes associated with SCA risk, we have provided evidence for causal associations between some, but not all, observational risk factors for SCA. We show that differences in CAD status, BMI, and QT interval are causally associated with SCA risk. While SCA is a complex disease with multiple influencing factors, a comprehensive genetic approach can untangle risk factor relationships, enhancing our understanding of SCA pathophysiology. Ultimately, genetic studies will enhance efforts to prevent SCA in high-risk populations and the general community.

## Supplementary material

Supplementary material is available at *European Heart Journal* online.

## Acknowledgements

The authors thank all the staff and participants from the studies contributing to this manuscript for their important contributions. AGNES: We thank L. Beekman for technical support and N. Bruinsma for assistance in collection of AGNES subject data, and Marie Cécile Perier and the Emergency medical mobile units which participated in the CARTAGENE study and the genetic INSERM Unit of François Cambien in Paris, particularly Carole Proust.

## Funding

AGNES: Netherlands Heart Foundation (Grant Numbers 2001D019, 2003T302, and 2007B202; grant 2005T024 to C.R.B.; CVON project PREDICT); the Leducq Foundation (Grant 05-CVD); the Center for Translational Molecular Medicine (CTMM COHFAR); and the Netherlands Organization for Scientific Research (NWO, grant ZonMW Vici Project number: 016.150.610 to C.R.B.). ARREST: Netherlands Heart Foundation, CVON project 2017-15 RESCUED; the European Union's Horizon 2020 research and innovation programme under acronym ESCAPE-NET (Grant Number 733381); the Netherlands Organization for Scientific Research (NWO, grant ZonMW Vici 918.86.616 to H.L.T.);

and the Medicines Evaluation Board Netherlands (CBG/MEB to H.L.T.). ARIC: National Heart, Lung, and Blood Institute (Contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C Grant Numbers R01HL087641, R01HL59367, and R01HL086694); National Human Genome Research Institute (Contract U01HG004402); National Institutes of Health (Contract HHSN268200625226C); the National Institutes of Health and NIH Roadmap for Medical Research (Grant Number UL1RR025005); and the National Institutes of Health (Grant Numbers R01HL11267 and R01HL116747 to F.N.A., R.N.M., A.M., and D.E.A.). CABS: National Heart, Lung, and Blood Institute (Grant Numbers HL111089, HL088456, HL088576, HL091244, HL116747, and HL092111); the Laughlin Family; and the John Locke and Medic One Foundations. CARTAGENE: French National Institute of Medical and Scientific Research (INSERM); Direction Générale de la Santé (French ministry of Health); and a French German grant BMBF-ANR for the genetic analyses. CHS: National Heart, Lung, and Blood Institute (Contract Numbers HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and Grant Numbers U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114); the National Institute of Neurological Disorders and Stroke; National Institute on Aging (Grant Number AG023629); National Center for Advancing Translational Sciences (Grant Number UL1TR001881); the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (Grant Number DK063491); the National Institutes of Health (Grant Numbers HL111089 and HL116747 to N.S.), and the Laughlin Family Endowment (to N.S.). A full list of CHS investigators and institutions can be found at <http://www.chs-nhlbi.org/pi.htm>. FHS: National Heart, Lung, and Blood Institute (Grant Numbers HL-54776 and HL-54776); and the United States Department of Agriculture Research Service (Contracts 53-K06-5-10 and 58-1950-9-001); the National Heart, Lung, and Blood Institute Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc. (Contract No. N02-HL-6-4278); and the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. FINGESTURE: Sigrid Juselius Foundation (Helsinki, Finland); the Council of Health of the Academy of Finland (Helsinki, Finland); and the Montreal Heart Institute Foundation. FINRISK: V.S. was supported by the Finnish Foundation for Cardiovascular Research. GEVAMI: University of Copenhagen (Copenhagen, Denmark); The Danish National Research Foundation (Copenhagen, Denmark); The John and Birthe Meyer Foundation (Copenhagen, Denmark); The Research Foundation of the Heart Center Rigshospitalet (Copenhagen, Denmark); and The Bikuben Scholar-Danmark-Amerika Fonden & Fulbright Commission (Copenhagen, Denmark). The KORA study was initiated and financed by the Helmholtz Zentrum München - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. HARVARD: National Heart, Lung, and Blood Institute (Grant Numbers HL-092111, HL-068070, HL-26490, HL-34595, HL-34594, HL-35464, HL-46959, and HL-080467) and the National Cancer Institute (Grant Numbers CA-34944, CA-40360, CA-55075, CA-87969, and CA-97193). ROTTERDAM: Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG



XII); the Municipality of Rotterdam; the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012); the Research Institute for Diseases in the Elderly (014-93-015; RIDE2); and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) (project nr. 050-060-810).

**Conflict of interest:** C.M.A. reports grants from NIH, during the conduct of the study. O.H.F. reports grants from Metagenics and Nestle, outside the submitted work. J.I.R. reports grants from NIH, during the conduct of the study. T.L. reports grants from NIH/NHLBI, during the conduct of the study; personal fees from 23AndMe, outside the submitted work. B.M.C.K. reports grants from US National Institutes of Health, during the conduct of the study. R.N.L. reports grants from NHLBI, during the conduct of the study. V.S. has participated in a conference trip sponsored by Novo Nordisk and received a honorarium from the same source for participating in an advisory board meeting. J.-C.T. reports grants from Amarin, grants from AstraZeneca, grants, personal fees and minor equity interest from DalCor, grants from Esperion, grants from Ionis, grants from Merck, grants and personal fees from Pfizer, grants and personal fees from Sanofi, grants and personal fees from Servier, outside the submitted work; in addition, Dr J.-C.T. has a patent Pharmaceogenomics-guided CETP inhibition pending, and a patent Diagnostic algorithm for statin-induced myotoxicity pending. M.V.D. reports grants from NIH, during the conduct of the study. T.E. reports personal fees from Astra zeneca, personal fees from Bayer AS, personal fees from Novo, personal fees from Boston Scientific, personal fees from Abbott, outside the submitted work. S.H. reports grants from NIH, during the conduct of the study. B.M.P. reports that he serves on the DSMB of a clinical trial funded by Zoll LifeCor and on the Steering Committee of the Yale Open Data Access Committee funded by Johnson & Johnson. D.E.A. reports grants from NHLBI, during the conduct of the study. All the other authors have no conflicts of interest to disclose.

## References

- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation* 2014;CIR.0000000000000152.
- Blom MT, Beesems SG, Homma PCM, Zijlstra JA, Hulleman M, van Hoeijen DA, Bardai A, Tijssen JGP, Tan HL, Koster RW. Improved survival after out-of-hospital cardiac arrest and use of automated external defibrillators. *Circulation* 2014;130:1868–1875.
- Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, Arbogast P, Raghunathan TE, Cobb LA. Family history as a risk factor for primary cardiac arrest. *Circulation* 1998;97:155–160.
- Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. *Circulation* 1999;99:1978–1983.
- Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW, Arnold AER, Boer M-J, D, Gorgels APM, Michels HR, Verkerk A, Verheugt FWA, Zijlstra F, Wilde AAM. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. *Circulation* 2006;114:1140–1145.
- Ackerman MJ. Genotype-phenotype relationships in congenital long QT syndrome. *J Electrocardiol* 2005;38:64–68.
- Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu L-F, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation* 2007;115:442–449.
- Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. *J Cardiovasc Electrophysiol* 2007;18:791–797.
- Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. *Eur Heart J* 2014;35:1917–1924.
- Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. *Int J Epidemiol* 2004;33:30–42.
- Voight B, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijnenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. *Lancet* 2012;380:572–580.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics* 2010;26:2190–2191.
- Chanda P, Huang H, Arking DE, Bader JS. Fast association tests for genes with FAST. *PLoS One* 2013;8:e68585.
- Johnson T. gtx: Genetics ToolboX [Internet]. 2013. Available from: <http://CRAN.R-project.org/package=gtx>.
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37:658–665.
- Causal associations between risk factors and common diseases inferred from GWAS summary data | bioRxiv [Internet]. [cited 2017 Oct 5]. Available from: <https://www.biorxiv.org/content/early/2017/07/26/168674>.
- Albert CM, McGovern BA, Newell JB, Ruskin JN. Sex differences in cardiac arrest survivors. *Circulation* 1996;93:1170–1176.
- Straus SMJM, Kors JA, De Bruin ML, van der Hoof CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MCJM, Stricker BHC, Witteman JCM. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol* 2006;47:362–367.
- Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, Kanoni S, Willenborg C, Burgess S, Amouyel P, Anand S, Blankenberg S, Boehm BO, Clarke RJ, Collins R, Dedoussis G, Farrall M, Franks PW, Groop L, Hall AS, Hamsten A, Hengstenberg C, Hovingh GK, Ingelsson E, Kathiresan S, Kee F, König IR, Koener J, Lehtimäki T, März W, McPherson R, Metspalu A, Nieminen MS, O'Donnell CJ, Palmer CNA, Peters A, Perola M, Reilly MP, Ripatti S, Roberts R, Salomaa V, Shah SH, Schreiber S, Siegbahn A, Thorsteinsdottir U, Veronesi G, Wareham N, Willer CJ, Zalloua PA, Erdmann J, Deloukas P, Watkins H, Schunkert H, Danesh J, Thompson JR, Samani NJ. Genetically determined height and coronary artery disease. *N Engl J Med* 2015;372:1608–1618.
- Cupples LA, Gagnon DR, Kannel WB. Long- and short-term risk of sudden coronary death. *Circulation* 1992;85:111–118.
- Arking DE, Junttila MJ, Goyette P, Huertas-Vazquez A, Eijgelsheim M, Blom MT, Newton-Cheh C, Reinier K, Teodoroescu C, Uy-Evanado A, Carter-Monroe N, Kaikkonen KS, Kortelainen M-L, Boucher G, Lagacé C, Moes A, Zhao XQing, Kolodjiev F, Rivadeneira F, Hofman A, Witteman JCM, Uitterlinden AG, Marsman RF, Pazoki R, Bardai A, Koster RW, Dehghan A, Hwang S-J, Bhatnagar P, Post W, Hilton G, Prineas RJ, Li M, Köttgen A, Ehret G, Boerwinkle E, Coresh J, Kao WHL, Psaty BM, Tomaselli GF, Sotoodehnia N, Siscovick DS, Burke GL, Marbán E, Spooner PM, Cupples LA, Jui J, Gunson K, Kesäniemi YA, Wilde AAM, Tardif J-C, O'Donnell CJ, Bezzina CR, Virmani R, Stricker B, H C h, Tan HL, Albert CM, Chakravarti A, Rioux JD, Huikuri HV, Chugh SS. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. *PLoS Genet* 2011;7:e1002158.
- Noseworthy PA, Havulinna AS, Porthan K, Lahtinen AM, Jula A, Karhunen PJ, Perola M, Oikarinen L, Kontula KK, Salomaa V, Newton-Cheh C. Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study/clinical perspective. *Circ Cardiovasc Genet* 2011;4:305–311.
- Albert CM, MacRae CA, Chasman DI, VanDenburgh M, Buring JE, Manson JE, Cook NR, Newton-Cheh C. Common variants in cardiac ion channel genes are associated with sudden cardiac death. *Circ Arrhythm Electrophysiol* 2010;3:222–229.



- F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Stefansson K, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Thorsteinsdottir U, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 2015;**518**:187–196.
30. Chen LY, Sotoodehnia N, Bůžková P, Lopex LF, Yee LM, Heckbert SR, Prineas R, Soliman EZ, Adabag S, Konety S, Folsom AR, Siscovick D, Alonso A. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. *JAMA Intern Med* 2013;**173**:29–35.
31. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana J-P, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. *Eur Heart J* 2005;**26**:2142–2147.
32. Brion M, Benyamin B, Visscher P, Smith G. Beyond the single SNP: emerging developments in Mendelian randomization in the “Omics” era. *Curr Epidemiol Rep* 2014;**1**:228–236.